top of page

12-year results of the phase III SOFT trial show a maintained disease-free survival benefit


As reported in the Journal of Clinical Oncology by Prudence A. Francis, MD, and colleagues, 12-year results of the phase III SOFT trial show a maintained disease-free survival benefit with the addition of ovarian function suppression to adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer. Clinically meaningful absolute improvements in overall survival were observed with the addition of ovarian function suppression to tamoxifen or exemestane in subgroups of high-risk patients.


44 views0 comments

Commentaires


bottom of page